



XINTELA DEVELOPS UNIQUE METHODS IN STEM CELL THERAPY FOR THE BRAIN AND BROADENS PATENT PORTFOLIO

Lund, Sweden, 17th of April 2018 - Xintela AB (publ) has developed new methods for identifying and purifying neural stem cells from the brain. This opens up a completely new field within the company's cell therapy business for the treatment of traumatic damage and diseases of the central nervous system (CNS).

"We believe this has very large potential and plan for further development once resources are available, either internally or through external collaboration partners," says Xintela's CEO Evy Lundgren-Åkerlund.

The results arose from the Company's ongoing research and development within regenerative medicine using its patented integrin marker technology. The new methods which have been developed on neural stem cells from mice, provide exiting prospects for stem cell therapy for regeneration of tissue after stroke or after trauma of the brain or spinal cord, as well as for the treatment or amelioration of symptoms in neurodegenerative diseases such as Alzheimer's and Parkinson's. Each of these indications is recognized as having very high unmet medical need and significant commercial potential.

Several international companies in the stem cell space have product development programs for CNS in preclinical and early clinical phases including treatment of stroke. Xintela's marker technology and methods to quality assure such stem cell products for therapeutic use can provide these companies significant value and advantages with regard to safety, efficacy and consistency, as well as major regulatory benefits. In addition, Xintela's new GMP manufacturing facility can produce stem cells for other stem cell companies, almost all of whom lack such manufacturing capability. Contract manufacturing can develop into another very attractive business for Xintela which has the potential to expand in line with the increased need for the production of stem cells in the growing field of regenerative medicine.

Xintela's new methods are protected by a patent application pending in the PCT phase. The application has received a positive international search report and written opinion from the European Patent Office (EPO) and was recently published. The new patent family, confers significant extensions in both patent term and in scope of protection, to the very broad exclusivity already provided by Xintela's framework of original stem cell and marker technology patents.

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy@xintela.se
Medicon Village
223 81 Lund
www.xintela.se

For investor relations and media questions, please contact:

Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
Email: marten.svanberg@laika.se
www.laika.se

Press release

Xintela AB (publ)

556780-3480

2018-04-17 08:30



About Xintela

Xintela develops medical products for regenerative medicine and cancer based on its proprietary marker technology, XINMARK®. Xintela uses the technology to select and assure the quality of mesenchymal stem cells for the treatment of cartilage damage and osteoarthritis. In a study on horses, the company has shown that stem cells are safe to use and that they have a positive effect on the articular cartilage and the underlying bone after an injury. In addition, Xintela has developed an assay XACT™ for the quality control chondrocyte preparations in cell therapy of cartilage. XINMARK® is also used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against glioblastoma, the most common and aggressive form of brain tumors in adults. Positive preclinical results from cell studies and animal model have shown that the antibody has a killing effect on glioblastoma cells and thus has confirmed the concept. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.